Mersana Therapeutics (MRSN) has disclosed a new risk, in the Accounting & Financial Operations category.
Mersana Therapeutics faces significant business risk due to its history of recurring losses from operations, raising doubts about its viability as a going concern. Despite having $134.6 million in cash and securities as of December 31, 2024, the company has never generated revenue or profit from product sales and may never do so. The need for additional capital to sustain future operations is critical, yet obtaining such funding on favorable terms is uncertain. This financial uncertainty could adversely affect stock prices and hinder relationships with potential collaborators and investors.
Overall, Wall Street has a Strong Buy consensus rating on MRSN stock based on 6 Buys.
To learn more about Mersana Therapeutics’ risk factors, click here.